Rite Aid Corporation (NYSE:RAD)

 

Rite Aid Corporation (NYSE:RAD), and Harmonyx, a leader in affordable and accessible genetic testing, declared recently the availability of select genetic tests in all Rite Aid pharmacies except those in New York state. Rite Aid is the first U.S. drugstore chain to offer Harmonyx genetic testing.

The self-administered oral swab test will assist patients determine the effectiveness of their prescription medication based on their genetic makeup. Presently, Rite Aid is offering genetic testing for three classes of medications counting those used to manage cardiac conditions, cholesterol and attention deficit hyperactivity disorder. Rite Aid pharmacists are available to assist patients and physicians determine if a particular test is medically appropriate.

“At Rite Aid, we are committed to offering our customers unique and innovative products, services and programs that meet their individual wellness needs, and personalized medication therapy through genetic testing is a perfect example of such a service,” said Jocelyn Konrad, Rite Aid executive vice president of pharmacy. “By offering Harmonyx genetic testing to our customers, we’re assisting to ensure that the medication they are taking is the most effective medication to assist them treat and manage their condition while avoiding unnecessary and potentially harmful side effects.”

Rite Aid Corporation (RAD), through its auxiliaries, operates a chain of retail drugstores in the United States. The company sells prescription drugs and a range of other merchandise, counting over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, and other every day and convenience products.

Kate Spade & Co (NYSE:KATE)

 

On Thursday, Kate Spade & Co (NYSE:KATE)’s shares inclined 4.37% to $21.03.

KATE its EPS ratio was 0.66. The company has 127.69 million shares outstanding while market capitalization of the company was $2.58 billion. Price to book ratio was -15.46. Net profit margin of the company was 6.80% while gross profit margin was 59.90%. Stock volatility for the month was booked as 5.33% while for the week was recorded as 4.75%.

The mean estimate for the short term price target for Kate Spade & Co (KATE) stands at $29.94 according to 16 Analysts. The higher price target estimate for the stock has been calculated at $40.00 while the lower price target estimate is at $19.00.

Analysts mean recommendation for the stock is 1.90. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.

Kate Spade & Company is engaged in the design and marketing of a range of accessories and apparel. The Company operates through three segments: KATE SPADE North America, KATE SPADE International and Adelington Design Group.

Imperva Inc (NYSE:IMPV)

 

Imperva Inc (NYSE:IMPV)’s shares gained 1.01% to $71.08.

IMPV has the market capitalization of $2.19 billion. The stock has P/B ratio of -9.63 while EPS was $-1.98. Institutional ownership of the company was 90.40% while 31.43 million shares were outstanding. Net profit margin of the Company was -26.10% while its gross profit margin was -26.10%. Share of the company moved above its SMA 50 with 7.30%. ROE ratio was -29.10% while ROI was -60.70%.

The mean estimate for the short term price target for Imperva Inc (IMPV) stands at $78.00 according to 18 Analysts. The higher price target estimate for the stock has been calculated at $88.00 while the lower price target estimate is at $48.00.

Analysts mean recommendation for the stock is 2.00. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.

Imperva, Inc. provides cyber-security solutions that protect business-critical data and applications. The Company’s suite of cyber-security offerings enables organizations to discover data and application assets and vulnerabilities, to protect information.

Cellectis SA (ADR) (NASDAQ:CLLS)

 

At the end of Thursday’s trade, Cellectis SA (ADR) (NASDAQ:CLLS)‘s shares dipped -1.81% to $36.36.

CLLS has market capitalization of $1.35 billion. Its current ratio was 4.70 while its shares were above its 50 days simple moving average with 20.55%. The company offered earning per share of $-0.29 while its 35.03 million shares were outstanding. YTD performance of the company was -7.48%. Stock volatility for the week was 8.48% while for the month it was shown at 7.01%.

The mean estimate for the short term price target for Cellectis SA (ADR) (CLLS) stands at $55.50 according to 4 Analysts. The higher price target estimate for the stock has been calculated at $65.00 while the lower price target estimate is at $44.00.

Analysts mean recommendation for the stock is 1.30. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.